Most gout care fails not because the diagnosis is mysterious, but because urate lowering is started, stopped, or left at a dose that never dissolves the crystal burden. For patients, that means “flares despite medication.” For clinicians, it means treating a measurable deposition disease without measuring to the target that matters: serum urate.

Why Hyperuricemia Becomes Gout

Hyperuricemia is the biochemical condition that permits monosodium urate crystals to form, usually when serum urate persistently exceeds its saturation point. Gout is the clinical inflammatory syndrome caused when the immune system reacts to those crystals in joints, bursae, tendons, or soft tissue. The distinction matters. An elevated urate level alone does not require drug therapy in most people, but gout with recurrent flares, tophi, erosive disease, or kidney stone history often does.

Treat-to-Target Is Not Optional Monitoring

The 2020 American College of Rheumatology guideline strongly endorses a treat-to-target strategy: adjust urate-lowering therapy until serum urate is below 6 mg/dL, rather than prescribing a fixed dose and hoping. EULAR recommendations similarly support maintaining urate below 6 mg/dL, and below 5 mg/dL in severe tophaceous gout, to accelerate crystal dissolution.

The reasoning is straightforward. Flares are the visible events, but crystals are the disease substrate. If urate remains above saturation, new crystals can form and old deposits persist. If urate is kept below target long enough, deposits shrink, flares decline, and tophi may resolve.

What Is Usually Monitored?

• Serum urate every few weeks during titration, then periodically once stable.
• Renal and hepatic function, because comorbid kidney disease and medications affect dosing.
• Flare frequency, tophi, adherence, alcohol intake, diuretics, and cardiovascular risk.

Choosing and Titrating Urate-Lowering Therapy

Allopurinol remains first-line for most patients, including many with chronic kidney disease, because it is effective, familiar, inexpensive, and supported by guideline evidence. The old habit of avoiding dose escalation in kidney disease has left many patients undertreated. Modern practice is to start low, commonly 100 mg daily or lower in advanced kidney disease, then titrate carefully to the urate target while monitoring safety.

Febuxostat is another xanthine oxidase inhibitor. Its cardiovascular safety has been debated: the CARES trial reported higher cardiovascular and all-cause mortality versus allopurinol in patients with established cardiovascular disease, while the FAST trial did not show increased cardiovascular death in a broader European population. That tension is why shared risk assessment matters, especially for patients with known cardiovascular disease.

An Illustrative Scenario

Consider a patient with three flares in one year, serum urate of 8.7 mg/dL, and mild chronic kidney disease. Starting allopurinol at 100 mg daily may be appropriate, but leaving it there is not a strategy. If urate remains 7.4 mg/dL after several weeks, dose titration is the therapeutic intervention. The target, not the starting dose, defines success.

Preventing Flares While Lowering Urate

One confusing feature of gout care is that starting urate-lowering therapy can temporarily increase flares. This is not treatment failure; it reflects mobilization of existing deposits. The ACR guideline strongly recommends anti-inflammatory prophylaxis when starting therapy, typically low-dose colchicine, nonsteroidal anti-inflammatory drugs, or glucocorticoids when appropriate, continued for at least three to six months and longer if flares persist.

Patients often stop allopurinol during a flare because the joint hurts and the medication seems implicated. In most established treatment plans, urate-lowering therapy is continued through flares; the flare is treated with anti-inflammatory medication. Stopping and restarting repeatedly produces urate swings, which can perpetuate the cycle.

Misconceptions That Keep Gout Undertreated

The most common misconception is that gout is simply a lifestyle disease. Diet, beer, spirits, fructose-sweetened beverages, obesity, kidney function, diuretics, genetics, and insulin resistance all influence urate biology, but severe gout is rarely solved by diet alone. Lifestyle changes help; they usually do not dissolve an established crystal burden without sustained urate lowering.

Another misconception is that a “normal” urate during an acute flare excludes gout. Serum urate can fall during inflammation, so aspiration showing negatively birefringent monosodium urate crystals remains the diagnostic gold standard when uncertainty is high. Imaging with ultrasound or dual-energy CT can also support diagnosis in selected cases.

Frequently Asked Questions

What uric acid level is the usual gout treatment target?

For many patients with gout, the usual serum urate target is below 6 mg/dL. A lower target may be considered for severe tophaceous gout when faster crystal dissolution is needed.

Can gout flares happen after starting allopurinol?

Yes. Flares can temporarily increase as urate deposits mobilize. This is why anti-inflammatory prophylaxis is often used during the first months of urate-lowering therapy.

Should allopurinol be stopped during a gout flare?

In most established treatment plans, urate-lowering therapy is continued during flares while the flare itself is treated with anti-inflammatory medication.

Where the Evidence Leaves Us

Treat-to-target urate lowering is one of the clearer examples in rheumatology where the biomarker is not a surrogate distraction; it is directly tied to crystal chemistry. Current evidence supports diagnosing gout carefully, starting urate-lowering therapy for patients with guideline-based indications, titrating to serum urate below 6 mg/dL, and protecting patients from mobilization flares during the transition.

Open questions include ideal targets for extensive tophi, prophylaxis duration, cardiovascular risk selection, and implementation in practice. The principle is clinically settled: treat urate to target.